Single Arm Phase II Study to Assess the Efficacy of Pembrolizumab Plus Radiotherapy or Ablation in Metastatic Colorectal Cancer Patients
Latest Information Update: 30 Sep 2024
At a glance
- Drugs Pembrolizumab (Primary)
- Indications Colorectal cancer
- Focus Therapeutic Use
Most Recent Events
- 20 Sep 2024 Status changed from active, no longer recruiting to completed.
- 08 Apr 2024 Planned End Date changed from 1 Apr 2024 to 1 Apr 2025.
- 08 Apr 2024 Planned primary completion date changed from 1 Apr 2024 to 1 Apr 2025.